Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL225145 | 0.94 | LTA4H (0.41) | LTA4HBACE1HRH3ESR1ESR2 | |
| SCHEMBL226369 | 0.93 | LTA4H (0.44) | LTA4HBACE1HRH3SIGMAR1ESR1 | |
| SCHEMBL226420 | 0.89 | ESR1 (0.46) | LTA4HHRH3ESR1ESR2KCNH2 | |
| SCHEMBL228344 | 0.89 | ESR1 (0.46) | LTA4HHRH3ESR1ESR2KCNH2 | |
| SCHEMBL228692 | 0.89 | ESR1 (0.46) | LTA4HHRH3ESR1ESR2KCNH2 | |
| SCHEMBL229775 | 0.89 | ESR1 (0.46) | LTA4HHRH3ESR1ESR2KCNH2 | |
| SCHEMBL225521 | 0.88 | ESR1 (0.46) | LTA4HHRH3ESR1ESR2KCNH2 | |
| SCHEMBL228090 | 0.87 | ESR1 (0.46) | LTA4HHRH3ESR1ESR2KCNH2 | |
| SCHEMBL227567 | 0.86 | LTA4H (0.42) | LTA4HBACE1HRH3ESR1ESR2 | |
| SCHEMBL229530 | 0.86 | HRH3 (0.47) | LTA4HBACE1HRH3SIGMAR1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | LTA4H 3180/4885BACE1 2935/4885HRH3 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.